Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma.

@article{Motzer1998PhaseIT,
  title={Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma.},
  author={Robert J Motzer and Ashok Rakhit and Lawrence H. Schwartz and Thomas E. Olencki and Thomas M Malone and Kate Sandstrom and Reginald A. Nadeau and Harish Parmar and Ronald M. Bukowski},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={1998},
  volume={4 5},
  pages={1183-91}
}
Patients with advanced renal cell carcinoma were treated in a Phase I trial with escalating doses of recombinant human interleukin-12 (rHuIL-12) given on days 1, 8, and 15 of each 28-day cycle. Treatment in the initial dose scheme consisted of a fixed dose with dose levels of 0.1, 0.5, and 1.0 microg/kg given to cohorts composed of three or six patients. On the basis of the toxicity profile, a second scheme (up-titration) was undertaken wherein rHuIL-12 was escalated for each patient from week… CONTINUE READING